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Abstract
Objectives—To study the stability of rheu-
matoid factor (RF) increases and to com-
pare the incidence of rheumatoid arthritis
(RA) in people with transient or persistent
increase of one or more RF isotypes.
Methods—From an original cohort of
nearly 14 000 participants in a population
study, 135 previously RF positive persons
were recruited in 1996 and evaluated
according to the 1987 ACR criteria. The
observation time ranged from 9–22 years
(mean 16.5). Blood samples were obtained
from all participants at entry and again in
1996.
Results—About 40% of the participants
who had only one raised RF isotype in the
original sample had become RF negative
in 1996 compared with only 15% of those
with increase of two or three RF isotypes
(p=0.002). The seven participants who
developed RA during the study period all
had persistently raised RF. Six of the 54
participants with more than one RF
isotype raised in 1996 developed RA,
corresponding to an annual incidence of
0.67%, which was 7.5 times higher than
observed in the other participants
(p=0.045).
Conclusion—Symptom free persons with
persistently raised RF have greatly in-
creased risk of developing RA. This sug-
gests that dysregulation of RF production
is a predisposing factor in RA.
(Ann Rheum Dis 2000;59:149–151)
Rheumatoid factor (RF) may play an impor-
tant part in normal immune responses1 and
increased RF is occasionally found in appar-
ently healthy people. Increased concentration
of RF is found in most rheumatoid arthritis
(RA) patients although it can also be increased
in other rheumatic diseases and in infections.
However, a combined increase of IgA and IgM
RF is almost exclusively found in RA and has
therefore a high diagnostic specificity for this
disease.2 Population surveys have shown that
the majority of people with increased RF do
not have symptoms of rheumatic diseases or
chronic infections.3 The role of RF in the
pathogenesis of RA is therefore not clear, and
reports are lacking on the stability of increased
RF isotypes and the risk of symptom free peo-
ple with persistenly raised RF to develop RA.
However, increase of RF has been found to
precede clinical symptoms of RA and the pre-
rheumatoid RF isotype patterns have been
similar to those observed in established
disease.3 4
Aho et al have estimated that the prevalence
of seropositive arthritis in Finland is approxi-
mately 0.5% in men and 1.1% in women,
increasing progressively from the age of 30 to
69 years, whereafter it seemed to level oV.4
Reports from other countries have shown an
overall prevalence of approximately 1%.5 The
annual incidence of RA in adult white popula-
tions has been reported to lie between 0.022
and 0.06% in diVerent studies.6 7 We have pre-
viously reported that symptom free people with
raised RF have increased risk of developing RA
compared with matched RF negative controls.3
This paper reports a serological and clinical
follow up on the previously seropositive
participants of this study with an average
observation time of 16.5 years.
Methods
STUDY BACKGROUND
A prospective health survey has been con-
ducted in the Reykjavík area by The Icelandic
Heart Association since November 1967. Col-
lection of data relating to rheumatic diseases
and RF started in 1968 and the original study
design has been described.3 Briefly, the partici-
pants were born between 1907 and 1935 and
selected randomly from all inhabitants in the
Reykjavík area of Iceland. Between 1974 and
1983 a total of 16 299 blood samples were col-
lected from 13 858 participants who were all
evaluated for symptoms of rheumatic diseases.
These blood samples were tested for RF by the
Rheumaton agglutination slide test, and posi-
tive samples were tested further by the
Rose-Waaler (RW) technique. All samples with
a RW titre of 1/10 or more were measured for
IgM, IgG and IgA RF isotypes by ELISA.8 The
participants were considered seropositive if
they had two or more RF isotypes above the
95% cut oV as determined by 200 randomly
selected age matched controls. Participants
with two RF isotypes under the 95% cut oV
level were only included if their third RF
isotype was above the 97.5% cut oV level.3
In 1987 all available RF positive participants
(n=173) and age and sex matched RF negative
participants (n=156) were evaluated clinically
and new blood samples collected. None of the
156 RF negative controls from the 1987 study
were included in this study.
SELECTION OF PARTICIPANTS FOR EVALUATION IN
1996
In addition to the 173 RF positive participants
in the 1987 study, 46 people who had been RF
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positive in the original blood sample but could
not be recruited to the study in 1987 were con-
sidered eligible for this study. Of these 219 per-
sons 52 had died in 1996. Of the 167 that were
thus potentially available 135 (81%) could be
recruited to this study, including 115 of the 173
seropositive participants from 1987 and 20
people who had previously been RF positive by
agglutination and ELISA but were unable to
participate in the 1987 study. The remaining
32 had either moved from the Reykjavik area or
could not be traced. The participants, 62 men
and 73 women, were all evaluated by struc-
tured interview and physical examination
according to the American College of Rheuma-
tism (ACR) criteria from 19879 without
knowledge of previous clinical or RF findings,
and new blood samples were collected. Thus,
at least two blood samples from each partici-
pant, taken at an interval of 9–22 years (mean
16.5) were tested for RF isotypes. It should be
noted that before 1987 RF had been measured
only by agglutination in a few of the partici-
pants. Thus, their isotypes were first measured
in 1987. As the incidence of RA was evaluated
in the context of RA isotypes in this study, an
observation time of only nine years could be
taken into account for these people.
MEASUREMENT OF RF
The ELISA for IgM, IgG and IgA RF has been
described in detail elsewhere.8 The sera were
tested at a dilution of 1/40 against a serial dilu-
tion of a local standard that had been calibrated
against an International Reference Preparation
(Statens Serum Institut, Copenhagen). Aggre-
gated rabbit IgG was used to block any free IgG
binding site on the solid phase bound RF. Two
RF positive control sera were included in each
test batch to monitor assay variability, which
was about 10%.
In 1996 RF values above the upper 95% cut
oV level (>25 AU/ml) for 200 normal subjects
were considered increased for each RF isotype.
STATISTICAL ANALYSIS
The results were analysed by the ÷2 test, or
Fisher’s exact test when appropriate. The level
of significance was set at p<0.05.
Results
STABILITY OF RF INCREASES
Of the 67 participants with two or three RF
isotypes increased in the original sample 47
(70%) still had two or more raised RF isotypes
9 to 22 years later, and only 10 (15%) had
become seronegative (table 1). In contrast, of
the 68 participants who had only one isotype
raised (97.5% cut oV) in the original sample 26
(38%) were seronegative (95% cut oV) in 1996
(p=0.002). Of the individual isotypes IgG RF
was less stable than IgM or IgA RF. However,
21 (31%) of the single positives had developed
an additional isotype increase and of these five
were diagnosed with RA (table 1). There was
not a significant association between RF stabil-
ity and age of the participants. It should be
noted that the 22 patients with RA all had per-
sistently raised RF, 16 had an increase of more
than one RF isotype in the original blood sam-
ple, and 20 had more than one RF isotype
increased in 1996, involving in all cases a com-
bined increase of IgM and IgA RF. Thus, the
prevalence of RA was 16% in the whole group
compared with 29% among participants with
increase of more than one RF isotype.
RA INCIDENCE AND RF STABILITY
Of the 135 participants, 15 had manifestations
of RA when the original blood samples were
collected in 1974–1987. As can be seen from
table 2 seven of the 120 symptom free
seropositive participants developed RA during
the observation period, which ranged from 9 to
22 years (mean 16.5), corresponding to an
average annual incidence rate of 0.35%.
However, none of the 36 participants who
became seronegative developed RA and only
one of 30 with persistently raised single RF
isotype, compared with six of 54 with an
increase of more than one RF isotype (table
3). The risk of developing RA was thus about
7.5 times greater in the last group than among
the remaining participants (p=0.045). It
should be noted that symptoms of RF did not
begin in any of the seven participants until at
least two years after the original blood sample
was obtained. Furthermore, none of the
participants had a history of symptoms
Table 1 Stability of increased RF isotypes and prevalence of RA during the follow up
period*
Increased RF isotypes in 1974–1987
Increased RF isotypes in 1996 (number of RA patients)
None One Two or three
One RF isotype 26 (38%) 21 (31%) 21 (31%)
(n=68) (0) (1) (5)†
Two or three RF isotype 10 (15%) 10 (16%) 47 (70%)
(n=67) (0) (1) (15)†
Total 36 (27%) 31 (23%) 68 (50%)
(n=135)‡ (0) (2) (20)†
*Numbers in parentheses show the 22 RA patients in relation to past and present RF findings. †All
these RA patients had an increase of both IgM and IgA RF. ‡115 of these 135 people participated
in the 1987 study and 20 had been RF positive in the original sample but could not be recruited
to the study in 1987. Thus, only previously RF positive people were included in this study.
Table 2 Incidence of RA in relation to RF findings in original blood samples from
1974–1987
Increased RF isotypes in original blood samples
Development of RA during the study period
Number
Follow up
period
(mean)
Annual
incidence (%)
One RF isotype (n=64) 2 (3.1%)* 15.6 0.20
Two or three RF istotypes (n=56) 5 (8.9%)† 17.7 0.50
Total (n=120) 7 (5.8%) 16.5 0.35
*One of these two patients had both IgM and IgA RF raised in his 1996 sample. †Four of these
patients had combined increase of IgM and IgA RF.
Table 3 Incidence of RA and RF findings in blood samples from 1996
Increased RF isotypes in 1996 blood sample
Development of RA during the study period
Number
Follow up
period
(mean)
Annual incidence
(95% confidence
intervals)‡
Group 1: No RF isotype (n=36) 0 (0%) 16.1 0% (0, 0.6)
Group 2: One RF isotype (n=30) *1 (3.3%) 16.8 0.2% (0.01, 1.04)
Group 3: Two or three RF istotypes (n=54) †6 (11.1%) 16.7 0.67% (0.25, 1.36)
Group 1 versus groups 2 and 3: p=0.074. Groups 1 and 2 versus group 3: p=0.045. *Isolated IgM
RF. †Five of these patients had two or three isotypes increased in the original blood sample. ‡The
approximate annual RA incidence and 95% confidence intervals in Finnish adults (>16 years) was
0.029 (0.025, 0.032).6
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suggesting that they might have developed a
transient RA that had subsided when this study
was carried out.
Discussion
In this study the long term stability of RF iso-
type increases was evaluated in the context of
prevalence of RA and the risk of developing
this disease. In agreement with previous
studies3 increase of RF was very stable (100%)
in the RA patients, but it was also relatively sta-
ble in participants who had still not developed
RA, especially in those with a combined
increase of IgM and IgA RF (74%).
The prevalence of RA has been estimated to
be approximately 1% among white
populations5 but it was 16% in our RF positive
study cohort. It is of interest that participants
with increased concentrations of both IgM and
IgA RF in 1996 had about 10 times higher
prevalence of RA than those who had become
seronegative or had only one persistently
increased RF istotype (table 1). This agrees
with the finding that IgM and IgA RF is char-
acteristic for RA patients.2 10 Eberhardt et al
have reported similiar RF isotype increases in
early RA11 and divergent findings may in part
be attributable to methodological diVerences.12
Increase of RF before clinical onset of RA is
well documented.3 12 13 The annual incidence
rate of RA has in several studies been reported
to be 0.022% to 0.06%,7 14 and in Finland the
annual incidence of seropositive RA was
estimated to be about 0.03% between 1980
and 1990.6 We have previously reported that
about 5% of 173 symptom free subjects with
increased RF developed RA during a mean
observation time of 9.6 years compared with
none of 156 age and sex matched RF negative
controls.3 Our present findings indicate that
people with an increase of more than one RF
isotype have an annual RA incidence of 0.67%,
which is about 22 times higher than was
observed for RF positive RA in the adult Finish
population between 1980 and 1990.6 Further-
more, epidemiological studies have shown an
annual incidence rates ranging from 0.074 to
0.157 for people over 40 years.14 However, the
mean age at diagnosis of RA increased from
50.2 to 57.8 years between 1975 and 1990.15 It
is not known whether this also applies to
Iceland.
In conclusion, our findings show that an
increase of RF is relatively stable even in symp-
tom free persons, especially when more than
one RF isotype is raised. Furthermore, symp-
tom free people with stable increase of RF have
a markedly increased incidence of RA, the pre-
dominant RF pattern being a combined
increase in IgM and IgA RF. The fact that
increases of RF can precede clinical disease for
a long period of time indicates that factors
regulating RF production may play a primary
part in the pathogenesis of RA.
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